COVID-19: an unexpected indication for anti-rheumatic therapies?
作者信息
Lucchino Bruno, Di Franco Manuela, Conti Fabrizio
机构信息
Rheumatology Unit, Department of Internal Clinical, Anesthesiologic and Cardiovascular Sciences, Sapienza University of Rome, Rome, Italy.
出版信息
Rheumatology (Oxford). 2020 Jun 1;59(6):1200-1203. doi: 10.1093/rheumatology/keaa194.
Abstract
摘要
相似文献
1
COVID-19: an unexpected indication for anti-rheumatic therapies?新冠病毒肺炎：抗风湿治疗的意外指征？
Rheumatology (Oxford). 2020 Jun 1;59(6):1200-1203. doi: 10.1093/rheumatology/keaa194.
2
What is the role of rheumatologists in the era of COVID-19?在新冠疫情时代，风湿病学家的作用是什么？
Autoimmun Rev. 2020 Jun;19(6):102539. doi: 10.1016/j.autrev.2020.102539. Epub 2020 Apr 3.
3
Thoughts on COVID-19 and autoimmune diseases.关于 COVID-19 和自身免疫性疾病的思考。
Lupus Sci Med. 2020 Apr 3;7(1):e000396. doi: 10.1136/lupus-2020-000396. eCollection 2020.
4
Baricitinib as rescue therapy in a patient with COVID-19 with no complete response to sarilumab.巴利昔替尼作为 COVID-19 患者对沙利鲁单抗无完全应答的补救治疗。
Infection. 2020 Oct;48(5):767-771. doi: 10.1007/s15010-020-01476-7. Epub 2020 Jul 8.
5
COVID-19: Review on latest available drugs and therapies against SARS-CoV-2. Coagulation and inflammation cross-talking.COVID-19：最新可用药物和 SARS-CoV-2 疗法综述。凝血与炎症相互作用。
Virus Res. 2020 Sep;286:198070. doi: 10.1016/j.virusres.2020.198070. Epub 2020 Jun 20.
6
Recommendations for coronavirus infection in rheumatic diseases treated with biologic therapy.生物制剂治疗的风湿性疾病合并冠状病毒感染的推荐建议。
J Autoimmun. 2020 May;109:102442. doi: 10.1016/j.jaut.2020.102442. Epub 2020 Apr 2.
7
Investigational Therapies for the Treatment of COVID-19: Updates from Ongoing Clinical Trials.治疗新型冠状病毒肺炎的研究性疗法：正在进行的临床试验的最新情况
Eur Urol Focus. 2020 Sep 15;6(5):1028-1031. doi: 10.1016/j.euf.2020.05.019. Epub 2020 Jun 5.
8
Baricitinib, a drug with potential effect to prevent SARS-COV-2 from entering target cells and control cytokine storm induced by COVID-19.巴瑞替尼，一种具有潜在作用的药物，可以阻止 SARS-COV-2 进入靶细胞，并控制由 COVID-19 引起的细胞因子风暴。
Int Immunopharmacol. 2020 Sep;86:106749. doi: 10.1016/j.intimp.2020.106749. Epub 2020 Jul 1.
9
Baricitinib as potential treatment for 2019-nCoV acute respiratory disease.巴瑞替尼作为2019新型冠状病毒急性呼吸道疾病的潜在治疗方法。
Lancet. 2020 Feb 15;395(10223):e30-e31. doi: 10.1016/S0140-6736(20)30304-4. Epub 2020 Feb 4.
10
Use of Hydroxychloroquine and Chloroquine During the COVID-19 Pandemic: What Every Clinician Should Know.在 COVID-19 大流行期间使用羟氯喹和氯喹：每个临床医生都应该知道的事。
Ann Intern Med. 2020 Jun 2;172(11):754-755. doi: 10.7326/M20-1334. Epub 2020 Mar 31.
引用本文的文献
1
SARS-CoV-2-induced venous thromboembolism in a patient with VEXAS syndrome.一名患有VEXAS综合征的患者出现了由严重急性呼吸综合征冠状病毒2（SARS-CoV-2）引起的静脉血栓栓塞。
Rheumatol Adv Pract. 2023 Jan 20;7(1):rkad012. doi: 10.1093/rap/rkad012. eCollection 2023.
2
Clinical Features and Outcomes of Coronavirus Disease 2019 in Patients with Inflammatory Bowel Disease and Spondyloarthropathies.炎症性肠病和脊柱关节炎患者 2019 年冠状病毒病的临床特征和结局。
Turk J Gastroenterol. 2022 Sep;33(9):751-759. doi: 10.5152/tjg.2022.22181.
3
An insight into SARS-CoV-2 structure, pathogenesis, target hunting for drug development and vaccine initiatives.对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的结构、发病机制、药物研发靶点探寻及疫苗研发进展的深入了解
RSC Med Chem. 2022 Jan 25;13(6):647-675. doi: 10.1039/d2md00009a. eCollection 2022 Jun 22.
4
Licorice () Extracts-Suitable Pharmacological Interventions for COVID-19? A Review.甘草提取物——对2019冠状病毒病合适的药理学干预措施？一篇综述。
Plants (Basel). 2021 Nov 26;10(12):2600. doi: 10.3390/plants10122600.
5
Baricitinib improves respiratory function in patients treated with corticosteroids for SARS-CoV-2 pneumonia: an observational cohort study.巴瑞替尼改善了 COVID-19 肺炎患者接受皮质类固醇治疗后的呼吸功能：一项观察性队列研究。
Rheumatology (Oxford). 2021 Jan 5;60(1):399-407. doi: 10.1093/rheumatology/keaa587.
6
Does immunosuppressive treatment entail an additional risk for children with rheumatic diseases? A survey-based study in the era of COVID-19.免疫抑制治疗是否会给患有风湿病的儿童带来额外的风险？COVID-19 时代的一项基于调查的研究。
Rheumatol Int. 2020 Oct;40(10):1613-1623. doi: 10.1007/s00296-020-04663-9. Epub 2020 Aug 2.
7
Why not to use colchicine in COVID-19? An oldanti-inflammatory drug for a novel auto-inflammatory disease.为何不在新冠肺炎治疗中使用秋水仙碱？一种用于新型自身炎症性疾病的古老抗炎药物。
Rheumatology (Oxford). 2020 Jul 1;59(7):1769-1770. doi: 10.1093/rheumatology/keaa217.
8
[Not Available].[无可用内容]
Rev Rhum Ed Fr. 2020 May;87(3):150-152. doi: 10.1016/j.rhum.2020.03.010. Epub 2020 Apr 24.
9
Old and new antirheumatic drugs for the treatment of COVID-19.用于治疗新型冠状病毒肺炎的新旧抗风湿药物
Joint Bone Spine. 2020 May;87(3):195-197. doi: 10.1016/j.jbspin.2020.03.013.
本文引用的文献
1
Increasing host cellular receptor-angiotensin-converting enzyme 2 expression by coronavirus may facilitate 2019-nCoV (or SARS-CoV-2) infection.冠状病毒增加宿主细胞表面受体血管紧张素转化酶 2 的表达可能有助于 2019-nCoV（或 SARS-CoV-2）感染。
J Med Virol. 2020 Nov;92(11):2693-2701. doi: 10.1002/jmv.26139. Epub 2020 Jul 2.
2
Reduction and Functional Exhaustion of T Cells in Patients With Coronavirus Disease 2019 (COVID-19).新型冠状病毒病（COVID-19）患者 T 细胞减少和功能耗竭。
Front Immunol. 2020 May 1;11:827. doi: 10.3389/fimmu.2020.00827. eCollection 2020.
3
Effective treatment of severe COVID-19 patients with tocilizumab.托珠单抗治疗重症 COVID-19 患者有效。
Proc Natl Acad Sci U S A. 2020 May 19;117(20):10970-10975. doi: 10.1073/pnas.2005615117. Epub 2020 Apr 29.
4
Molecular immune pathogenesis and diagnosis of COVID-19.新型冠状病毒肺炎的分子免疫发病机制与诊断
J Pharm Anal. 2020 Apr;10(2):102-108. doi: 10.1016/j.jpha.2020.03.001. Epub 2020 Mar 5.
5
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.羟氯喹和阿奇霉素治疗 COVID-19：一项开放标签非随机临床试验的结果。
Int J Antimicrob Agents. 2020 Jul;56(1):105949. doi: 10.1016/j.ijantimicag.2020.105949. Epub 2020 Mar 20.
6
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).羟氯喹治疗严重急性呼吸综合征冠状病毒 2 （SARS-CoV-2）的体外抗病毒活性和优化剂量设计预测。
Clin Infect Dis. 2020 Jul 28;71(15):732-739. doi: 10.1093/cid/ciaa237.
7
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.严重急性呼吸综合征冠状病毒 2 型（SARS-CoV-2）进入细胞依赖于 ACE2 和 TMPRSS2，可被一种临床验证的蛋白酶抑制剂所阻断。
Cell. 2020 Apr 16;181(2):271-280.e8. doi: 10.1016/j.cell.2020.02.052. Epub 2020 Mar 5.
8
Understanding SARS-CoV-2-Mediated Inflammatory Responses: From Mechanisms to Potential Therapeutic Tools.理解 SARS-CoV-2 介导的炎症反应：从机制到潜在的治疗工具。
Virol Sin. 2020 Jun;35(3):266-271. doi: 10.1007/s12250-020-00207-4. Epub 2020 Mar 3.
9
COVID-19: combining antiviral and anti-inflammatory treatments.2019冠状病毒病：联合抗病毒与抗炎治疗
Lancet Infect Dis. 2020 Apr;20(4):400-402. doi: 10.1016/S1473-3099(20)30132-8. Epub 2020 Feb 27.
10
Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention.中国2019年冠状病毒病（COVID-19）疫情的特征及重要经验教训：来自中国疾病预防控制中心72314例病例报告的总结
JAMA. 2020 Apr 7;323(13):1239-1242. doi: 10.1001/jama.2020.2648.
Zotero 插件